Freeline is a clinical-stage biotechnology company developing transformative adeno-associated virus (AAV) vector-mediated systemic gene therapies.

They are dedicated to improving patient lives through innovative, one-time treatments. Freeline use their proprietary, rationally designed AAV vector and capsid (AAVS3), along with novel promoters and transgenes, to deliver a functional copy of a therapeutic gene into human liver cells to express a persistent functional level of the missing or dysfunctional protein into the patient’s bloodstream.

They are advancing clinical programmes in Gaucher disease and Fabry disease.